Business Wire

NJ-IEEE

15.11.2021 16:32:07 CET | Business Wire | Press release

Share
City of Vienna Earns IEEE AI Ethics Certification Mark; Reinforcing Commitment to Digital Humanism Strategy

IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced that the City of Vienna has become the first city worldwide to earn the IEEE CertifiAIEd AI Ethics (AIE) Certification Mark to advance the city’s Digital Humanism strategy.

"With artificial intelligence, we can make many tasks in administration more efficient and faster. As the City of Vienna, we are taking on a pioneering role here," says Peter Hanke, City Councillor for Economic Affairs. "Particularly in direct contact with people and especially in dealing with data, caution is required. People are at the center of our considerations."

The IEEE CertifAIEd mark recognizes that a product, service, or system has been verified to meet relevant ethical criteria, contributing towards a greater level of confidence and demonstrating a proactive approach to building public trust in AI systems. There are currently four sets of criteria available for IEEE CertifiAIEd certification:

  • Transparency criteria relate to values embedded in a system design, and the openness and disclosure of choices made for development and operation.
  • Accountability criteria recognize that the system/service autonomy and learning capacities are the results of algorithms and computational processes designed by humans and organizations that remain responsible for their outcomes.
  • Algorithmic bias criteria relate to the prevention of systematic errors and repeatable undesirable behaviors that create unfair outcomes.
  • Privacy criteria are aimed at respecting the private sphere of life and public identity of an individual, group, or community, upholding dignity.

“IEEE has laid the groundwork for AI Ethics based on principles and standards created by hundreds of our volunteers over the past five years, which are already having a global impact,” said Konstantinos Karachalios, Managing Director of IEEE SA. “IEEE CertifAIEd represents our continued evolution of the AI Ethics ecosystem by establishing a program to inspire trust and a means towards responsible implementation of AI systems that demonstrates an organization’s commitment to upholding human values, dignity, and well-being, and to respecting, protecting and preserving fundamental human rights. We are honored to work with the City of Vienna to support their Digital Humanism platform and to provide the mark for responsible innovation required in today’s world to inspire certified trust for their AI Systems.”

IEEE’s CertifAIEd program aims to enhance confidence in public and private enterprises that realize the benefits of AI ethics by earning certification in the absence of or as a complement to broadly accepted and enforced regulations for AI. As proposed legislation in the EU would require conformity certification for any AI based systems to mitigate any unintended risks, the City of Vienna is addressing these risks and demonstrating the benefits of responsible government innovation by earning the IEEE CertifAIEd mark. In doing so, it sets a precedent for other cities and entities to achieve their aims in a responsible and human-centric manner.

"Data security and data protection must be at the forefront when using AI from the very beginning. That's why we relied on international expertise during the development of the software and had our program ethically certified," said Deputy Director General, Peter Weinelt.

Cities, entities, and individuals interested in learning more about the criteria or getting involved in the program can visit the IEEE CertifAIEd website .

To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook , follow us on Twitter , connect with us on LinkedIn , or on the Beyond Standards Blog .

About the IEEE Standards Association

IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer and sustainable world. For more information, visit https://standards.ieee.org .

About IEEE

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org .

Link:

ClickThru

Social Media:

https://www.facebook.com/ieeesa/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye